Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab for Refractory Uveitis in Behçet's Disease
NCT04218565Phase 2Terminated
- Start
- Feb 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of golimumab in Behçet's disease (BD). Started Feb 2020; status: terminated.
02
Drugs
golimumab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT04218565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04218565.